— Know what they know.
Not Investment Advice

VIGL NASDAQ

Vigil Neuroscience, Inc.
1W: -0.1% 1M: +0.8% 3M: +178.6% 1Y: +100.8% 3Y: +21.1%
$8.05
Last traded 2025-08-05 — delisted
NASDAQ · Healthcare · Biotechnology · $375.7M mcap · 31M float · 5.28% daily turnover · Short 38% of daily vol

Balance Sheet Trends

Total Assets
$118M -16.4% ▼
4Y CAGR: +46.9%
Total Liabilities
$46M +87.2% ▲
4Y CAGR: -3.7%
Shareholders Equity
$72M -38.4% ▼
Cash & Investments
$98M -17.1% ▼
4Y CAGR: +41.9%
Total Debt
$13M -6.5% ▼
4Y CAGR: +1337.7%
Net Debt
-$26M +31.6% ▲

Assets vs Liabilities & Equity

Year-over-Year Growth

View Full Balance Sheet
Line ItemFY2020FY2021FY2022FY2023FY2024
— Assets —
Cash$24M$91M$187M$52M$39M
Short-Term Investments$0$0$0$66M$59M
Cash & ST Investments$24M$91M$187M$118M$98M
Net Receivables$0$0$15K$1M$599K
Inventory$0$0$0$0$0
Other Current Assets$70K$359K-$3M$797K$846K
Total Current Assets$25M$97M$198M$122M$101M
Property, Plant & Equip.$0$1M$1M$18M$16M
Goodwill & Intangibles$0$0$0$0$0
Long-Term Investments$0$0$927K$0$0
Other Non-Current Assets$0$4M$266K$1M$1M
Total Non-Current Assets$0$5M$3M$19M$17M
Total Assets$25M$102M$200M$141M$118M
— Liabilities —
Accounts Payable$1M$4M$2M$2M$2M
Short-Term Debt$0$873K$176K$0$0
Deferred Revenue$0$0$0$0$20M
Other Current Liabilities$376K-$214K$6M$324K$289K
Total Current Liabilities$2M$10M$11M$12M$34M
Long-Term Debt$303$0$0$0$0
Other Non-Current Liab.$52M$162M$0$0$0
Total Non-Current Liabilities$52M$162M$2M$13M$12M
Total Liabilities$54M$172M$11M$25M$46M
— Equity —
Common Stock$0$0$4K$4K$4K
Retained Earnings-$29M-$72M-$140M-$223M-$307M
Accumulated OCI$0$0$0-$5K$27K
Total Stockholders Equity-$28M$92M$189M$116M$72M
Total Liabilities & Equity$25M$102M$200M$141M$118M
— Key Metrics —
Total Debt$303$937K$176K$14M$13M
Net Debt-$24M-$90M-$186M-$38M-$26M
Total Investments$0$0$927K$66M$59M

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms